MannKind slips on Afrezza PDUFA extension

MannKind Corp. (NASDAQ:MNKD) slipped $0.55 to $6.32 on Monday after FDA extended by three months the PDUFA date for a resubmitted NDA for Afrezza to improve glycemic control in Type I and II diabetics...